Subscribe

Noile-Immune Biotech Inc. (4893.T)

JPY139.00 +5.00 (+3.73%)
JP JPX Healthcare Biotechnology
Address 2-12-10 105-0012
Minato, JP
CEO Koji Tamada
Website noile-immune.com
IPO 2023-06-28
ISIN JP3759560000

Explore sections of this company profile

Description

Established in 2015 and based in Minato, Japan, this company is dedicated to exploring and advancing CAR-T cell technology for use in cancer immunotherapy treatments.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
JPY139.00 +5.00 (+3.73%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
198.1K
Beta
0.06
Float Shares
17.00M
Free Float %
39.3%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
-4.93% -12.34% -10.00% -15.63% -12.90% +0.75% -14.01% -81.12% -81.12% -81.12% -81.12%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
139.00
DCF (Unlevered) 90.22 -35.1%
DCF (Levered) 89.50 -35.6%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 100% Bullish
Rating 2026-05 Change
Strong Buy 0 0
Buy 1 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
54.62
Safe zone
Piotroski F-Score
3 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
  • ✗
    Revenue growth Biotechnology: +1.6%
    -34.1% Q1'26: -100.0% (vs Q1'25)
  • ✗
    EPS growth Biotechnology: +29.7%
    +17.7% Q1'26: +36.2% (vs Q1'25)
  • ✗
    FCF margin FCF growth · Biotechnology: +16.2%
    -104.9%
  • ✗
    EBIT margin Biotechnology: +0.0%
    -15,945.1%
  • ✗
    ROIC Biotechnology: -16.1%
    -5,854.4% Q1'26: -2,311.2% (vs Q1'25)
  • ✗
    Share dilution Biotechnology: -3.4%
    +0.0% ★ Q1'26: 0.0% (vs Q1'25)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×
    0.00× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples From To
DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.09) × ERP
WACC = 100% × Ke + 0% × Kd (4.3%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 90.22 Current price: 139.00
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
1 Rev. Ana.
1 EPS Ana. 		Dec 2027
1 Rev. Ana.
1 EPS Ana. 		Dec 2028
1 Rev. Ana.
1 EPS Ana. 		Dec 2029
1 Rev. Ana.
1 EPS Ana. 		Dec 2030
1 Rev. Ana.
1 EPS Ana.
Revenue
316.82M
est: 319.00M (-0.7%)
7.59M
est: 319.00M (-97.6%)
5.00M
est: 300.00M (-98.3%)
300.00M
300.00M – 300.00M
+0.0% YoY
300.00M
300.00M – 300.00M
+0.0% YoY
3.10B
3.10B – 3.10B
+933.3% YoY
300.00M
300.00M – 300.00M
-90.3% YoY
300.00M
300.00M – 300.00M
+0.0% YoY
EBITDA
-775.39M
est: -266.04M (-191.5%)
-1.07B
est: -266.04M (-301.9%)
-797.25M
est: -250.20M (-218.7%)
-250.20M
-250.20M – -250.20M
+0.0% YoY
-250.20M
-250.20M – -250.20M
+0.0% YoY
-2.59B
-2.59B – -2.59B
-933.3% YoY
-250.20M
-250.20M – -250.20M
+90.3% YoY
-250.20M
-250.20M – -250.20M
+0.0% YoY
EBIT
-775.39M
est: -266.04M (-191.5%)
-1.07B
est: -266.04M (-301.9%)
-797.25M
est: -250.20M (-218.7%)
-250.20M
-250.20M – -250.20M
+0.0% YoY
-250.20M
-250.20M – -250.20M
+0.0% YoY
-2.59B
-2.59B – -2.59B
-933.3% YoY
-250.20M
-250.20M – -250.20M
+90.3% YoY
-250.20M
-250.20M – -250.20M
+0.0% YoY
Net Income
-1.13B
est: -1.83B (+38.4%)
-964.46M
est: -903.71M (-6.7%)
-793.54M
est: -1.21B (+34.6%)
-793.72M
-793.72M – -793.72M
+34.5% YoY
-1.04B
-1.04B – -1.04B
-30.9% YoY
1.34B
1.34B – 1.34B
+229.2% YoY
-1.21B
-1.21B – -1.21B
-190.3% YoY
-1.34B
-1.34B – -1.34B
-10.7% YoY
SGA
443.25M
est: 4.70B (-90.6%)
496.70M
est: 10.15B (-95.1%)
441.38M
est: 9.54B (-95.4%)
9.54B
9.54B – 9.54B
+0.0% YoY
9.54B
9.54B – 9.54B
+0.0% YoY
98.61B
98.61B – 98.61B
+933.3% YoY
9.54B
9.54B – 9.54B
-90.3% YoY
9.54B
9.54B – 9.54B
+0.0% YoY
EPS
-27.25
est: -42.38 (+35.7%)
-22.26
est: -20.87 (-6.7%)
-18.33
est: -28.00 (+34.5%)
-18.33
-18.33 – -18.33
+34.5% YoY
-24.00
-24.00 – -24.00
-30.9% YoY
31.00
31.00 – 31.00
+229.2% YoY
-28.00
-28.00 – -28.00
-190.3% YoY
-31.00
-31.00 – -31.00
-10.7% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-15 C 2/5 3/5 1/5 1/5 1/5 1/5 4/5
2026-05-14 C 2/5 3/5 1/5 1/5 1/5 1/5 4/5
2026-05-13 C 2/5 3/5 1/5 1/5 1/5 1/5 4/5
2026-05-12 C 2/5 3/5 1/5 1/5 1/5 1/5 4/5
2026-05-11 C 2/5 3/5 1/5 1/5 1/5 1/5 4/5
2026-05-08 C 2/5 3/5 1/5 1/5 1/5 1/5 4/5
2026-05-07 C 2/5 3/5 1/5 1/5 1/5 1/5 4/5
2026-05-01 C 2/5 3/5 1/5 1/5 1/5 1/5 4/5
2026-04-30 C 2/5 3/5 1/5 1/5 1/5 1/5 4/5
2026-04-28 C 2/5 3/5 1/5 1/5 1/5 1/5 4/5
2026-04-27 C 2/5 3/5 1/5 1/5 1/5 1/5 4/5
2026-04-24 C 2/5 3/5 1/5 1/5 1/5 1/5 4/5
2026-04-23 C 2/5 3/5 1/5 1/5 1/5 1/5 4/5
2026-04-22 C 2/5 3/5 1/5 1/5 1/5 1/5 4/5
2026-04-21 C 2/5 3/5 1/5 1/5 1/5 1/5 4/5
2026-04-20 C 2/5 3/5 1/5 1/5 1/5 1/5 4/5
2026-04-17 C 2/5 3/5 1/5 1/5 1/5 1/5 4/5
2026-04-16 C 2/5 3/5 1/5 1/5 1/5 1/5 4/5
Ownership data is not available for this company yet.

Executive team

Top executives
EBIT / Employee
-318.9K
Shares Outstanding
43.30M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Hiroko Nagai Chief Financial Officer, GM of Administration & Director — female
Koji Tamada President, Chief Executive Officer & Chairman — male
Tsutomu Tokashiki Chief Operating Officer, GM of Business Planning & Research Department and Director — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Biotechnology